Stallergenes Greer

Stallergenes Greer International AG is a global biopharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.[2]

Stallergenes Greer
TypePrivate
IndustryPharmaceutical industry
Founded2015 (2015)
HeadquartersBaar, Switzerland
Key people
Stefan Meister (Chairman), Michele Antonelli (Chief Executive Officer), Giampiero De Luca (Board member)
RevenueIncrease € 277 million (2018) [1]
12,8 M€ (2018)
Number of employees
1045 (2021)

Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc.[3] (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France).[4]

With 1035 employees in 2021,[5] Stallergenes Greer operates in 19 countries.[6]

Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France) and in the USA (Lenoir, North Carolina and San Diego, California).[7]

History

Stallergenes was founded in 1962 by Institut Mérieux [8][9][10][11] In 2015, Stallergenes and Greer Laboratories Inc. merged to form Stallergenes Greer, "a worldwide leader in allergy immunotherapy".[12][13]

Greer was founded by R.T. Greer, a collecter of source materials (i.e. : roots, herbs, pollens) in 1904.[14]

Stallergenes Greer is a privately held company owned by B-Flexion (ex Waypoint Capital), chaired by Ernesto Bertarelli.[15]

Activity

Stallergenes Greer is specialised in allergy immunotherapy treatments. It includes Name Patient Products (NPP) which are allergen products, prepared in accordance with prescriptions for individual patients.[16]

The product portfolio covers different segments including: sublingual products (Staloral®, Oralair®, Actair®), subcutaneous products (Alustal®/Phostal®, Alyostal®/Albey®), allergen extracts available as bulk extract or NPP, veterinary products, testing supplies, source materials and other supplies like sterile diluents, sterile empty vials.

Board of directors

The board of directors includes:[17][18]

  • Stefan Meister, Chairman
  • Michele Antonelli, Chief Executive Officer
  • Giampero De Luca, Board member

A pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies. [19]

Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.[20][21]

The second project in this programme is the house dust mite immunotherapy tablet Actair which is marketed in Japan, Australia, and New Zealand,[22][23] and South Korea under the brand name Actair and in Germany under the brand name Orylmyte.[24]

In 2021, Stallergenes Greer is partnering with Aptar Pharma to develop novel connected device for allergen immunotherapy treatment delivery. It will contribute to improving adherence, thus optimising treatment outcomes.[25]

References
  1. "Annual report" (PDF). stallergenesgreer.com. 2018.
  2. "STALLERGENES GREER LTD". Companies House.
  3. "STALLERGENES GREER LTD". Companies House.
  4. "STALLERGENES SAS". infogreffe.fr.
  5. "Key facts and figures". stallergenesgreer.com.
  6. "Global Network | stallergenesgreer.com". www.stallergenesgreer.com. Retrieved 2020-05-21.
  7. "Annual Report 2018" (PDF). 2018.
  8. "Stallergenes Greer". Ville d'Antony. Archived from the original on 2019-10-25.
  9. "Le leader de la lutte contre les allergies fête ses 50 ans". Le Parisien. 12 December 2012.
  10. "Grand Oralair". Les Echos. 3 April 2014.
  11. "COR-Stallergènes envisage des acquisitions en 2013". Challenges. 21 December 2012.
  12. "Labos: fusion de Stallergenes et Greer bouclée". Le Figaro. 8 September 2015.
  13. "Stallergenes and Greer to create the World Leader in Allergy Immunotherapy - Labiotech.eu". 30 June 2015.
  14. "History - stallergenesgreer.com". stallergenesgreer.com.
  15. "Stallergenes Greer : Waypoint détient la totalité du capital ; sortie du marché ce 17 mai". 17 May 2019.
  16. "Collège de la Haute Autorité de Santé - Projet de recommandation" (PDF). Haute autorité de santé. 13 December 2017.
  17. "BOARD OF DIRECTORS". Retrieved 2019-10-25.
  18. "Stallergenes : résultats semestriels en hausse, changement de direction". capital.fr. 30 August 2018.
  19. "Stallergènes Anti-allergènes sur mesure". 30 June 2005.
  20. "Aux États-Unis, Stallergenes impose ses anti-allergiques". 10 April 2014.
  21. "Le spécialiste des allergies à l'assaut des Etats-Unis". 8 April 2014.
  22. "Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer's Sublingual House Dust Mite Allergen Immunotherapy Tablet". financialpost. Retrieved 2021-09-14.
  23. "Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint". Business Wire. 20 November 2018.
  24. "Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer's Sublingual House Dust Mite Allergen Immunotherapy Tablet". businesswire.com. 31 May 2021.
  25. "Stallergenes Greer choisit Aptar pour son dispositif médical connecté". usinenouvelle.com. 21 November 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.